All In Biotech

Drug Trial Radar · NCT06414590

Neoadjuvant Tebentafusp for Uveal Melanoma

Neoadjuvant Tebentafusp in Patients With Locally Advanced, Unresectable Primary Uveal Melanoma

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

19

Planned (sponsor's estimate)

Start

Sep 5, 2025

Primary completion

Aug 2027

Study completion Mar 2032

Sponsor

Lead sponsor
Thomas Jefferson UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Immunocore Ltd
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single arm, phase II clinical trial of neoadjuvant Tebentafusp (KIMMTRAK®) in patients with locally advanced primary uveal melanoma. Patients must be HLA-A\*02:01 with large, surgically unresectable (other than complete enucleation of the eye) primary uveal melanoma. The efficacy of this treatment will be assessed with the Simon's two stage design. The choice of design is guided by a desire to stop the trial early if the actual regression rate of primary uveal melanoma is 1% or lower.

Conditions

  • Locally Advanced Unresectable Uveal Melanoma

Interventions

  • Tebentafusp-TebnDrug

    Tebentafusp will be administered as follows: 20mcg on Day 1, 30mcg on Day 8, 68 mcg on Day 15, and weekly doses of 68 mcg thereafter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Regression of primary uveal melanoma after Tebentafusp treatment in 20% of treated patients.Time frame: 3 months post-eye treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Wills Eye Hospital

    Philadelphia, Pennsylvania · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.